ES2184808T3 - Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12. - Google Patents

Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12.

Info

Publication number
ES2184808T3
ES2184808T3 ES95933488T ES95933488T ES2184808T3 ES 2184808 T3 ES2184808 T3 ES 2184808T3 ES 95933488 T ES95933488 T ES 95933488T ES 95933488 T ES95933488 T ES 95933488T ES 2184808 T3 ES2184808 T3 ES 2184808T3
Authority
ES
Spain
Prior art keywords
demelinizing
lofepramine
phenylalanine
vitamin
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95933488T
Other languages
English (en)
Inventor
Cari Loder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9420116A external-priority patent/GB9420116D0/en
Priority claimed from GBGB9508482.8A external-priority patent/GB9508482D0/en
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2184808T3 publication Critical patent/ES2184808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Fodder In General (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Control Of El Displays (AREA)

Abstract

EL USO DE UNA COMBINACION DE UN ANTIDEPRESOR TRICICLICO O TETRACICLICO , UN INHIBIDOR DE LA RECAPTACION DE SEROTONINA, O UN INHIBIDOR DE LA OXIDASA MONOAMINO CON UN INDUCTORNEUROTRANSMISOR O COMPUESTO PRECURSOR ESTA PENSADO PARA LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PREVENCION DE LA ESCLEROSIS MULTIPLE U OTRAS AFECCIONES DESMIELINIZANTES. EN EL USO DEL TRATAMIENTO DE MEJORA DE LOS EFECTOS DE UNA AFECCION DESMIELINIZANTE , SE CONSIDERA UN REGIMEN DIARIO DE 10 A 220 MG. DE LOFEPRAMINA Y DE 100 MG. A 5 G DE L-FENILALANINA, SUPLEMENTADO DIARIAMENTE CON INYECCIONES DE VITAMINA B{SUB,12}.
ES95933488T 1994-10-05 1995-10-05 Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12. Expired - Lifetime ES2184808T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9420116A GB9420116D0 (en) 1994-10-05 1994-10-05 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions
GBGB9508482.8A GB9508482D0 (en) 1995-04-26 1995-04-26 A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product

Publications (1)

Publication Number Publication Date
ES2184808T3 true ES2184808T3 (es) 2003-04-16

Family

ID=26305745

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95933488T Expired - Lifetime ES2184808T3 (es) 1994-10-05 1995-10-05 Tratamiento de la esclerosis multiple (em) y otro estados desmielinizantes empleando lofepramina en combinacion con l-fenilalanina, tirosina o triptofano y opcionalmente un compuesto de vitamina b12.

Country Status (19)

Country Link
US (2) US6096737A (es)
EP (1) EP0784476B1 (es)
JP (1) JPH10508583A (es)
AT (1) ATE227124T1 (es)
AU (1) AU710339B2 (es)
CA (1) CA2200761C (es)
CZ (1) CZ293873B6 (es)
DE (1) DE69528773T2 (es)
DK (1) DK0784476T3 (es)
ES (1) ES2184808T3 (es)
FI (1) FI116659B (es)
HU (1) HU225493B1 (es)
IS (1) IS1956B (es)
NO (1) NO314486B1 (es)
NZ (1) NZ293642A (es)
PL (1) PL181802B1 (es)
PT (1) PT784476E (es)
SK (1) SK281932B6 (es)
WO (1) WO1996011009A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69715899T2 (de) * 1996-07-05 2003-05-28 The Wwk Trust, Kent Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten
GB9617990D0 (en) * 1996-08-29 1996-10-09 Scotia Holdings Plc Treatment of pain
EP0835660A1 (en) * 1996-10-14 1998-04-15 Gaston Edmond Filomena Merckx Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions
US7232830B2 (en) * 1998-06-26 2007-06-19 Elaine A Delack Method for treatment of neurodegenerative diseases and effects of aging
GB9904252D0 (en) * 1999-02-24 1999-04-21 Worsley Andrew P Composition for the treatment of pain
GB9906808D0 (en) * 1999-03-24 1999-05-19 Kilgowan Limited Formulation for treatment of pain
GB2355191A (en) * 1999-10-12 2001-04-18 Laxdale Ltd Combination formulations for fatigue, head injury and strokes
AU2001279313B2 (en) 2000-08-04 2007-03-01 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20020147206A1 (en) * 2001-04-05 2002-10-10 Pfizer Inc. Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
GB0216027D0 (en) 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US7169752B2 (en) * 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US6833142B2 (en) * 2002-03-14 2004-12-21 Duane Bennett Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions
ATE520981T1 (de) 2002-10-02 2011-09-15 Dmi Biosciences Inc Diagnose und überwachung von krankheiten
WO2004073614A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of immunoinflammatory disorders
CA3050734A1 (en) 2003-05-15 2004-12-02 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
GB0313630D0 (en) * 2003-06-12 2003-07-16 Wwk Trust The Compositions for the enhanced treatment of depression
TW200522932A (en) * 2003-09-15 2005-07-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
ATE552832T1 (de) 2006-02-24 2012-04-15 Shire Llc Antidepressivum-propharmaka
WO2009146320A1 (en) 2008-05-27 2009-12-03 Dmi Life Sciences, Inc. Therapeutic methods and compounds
WO2011011594A2 (en) * 2009-07-23 2011-01-27 Shriners Hospitals For Children Intracellular toll-like receptors pathways and axonal degeneration
US8507496B2 (en) 2010-09-07 2013-08-13 Dmi Acquisition Corp. Treatment of diseases
EA027343B1 (ru) 2011-10-10 2017-07-31 Ампио Фармасьютикалз, Инк. Имплантируемые устройства медицинского назначения с повышенной иммунной толерантностью и способы изготовления и имплантирования
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
CA2846394A1 (en) 2011-10-28 2013-05-02 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
BR112015020469A2 (pt) 2013-03-15 2020-01-28 Ampio Pharmaceuticals Inc Usos de da-dkp, composição e método para fornecimento de células-tronco a umindivíduo
AU2015305611B2 (en) 2014-08-18 2020-04-23 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
GB2544630A (en) 2015-11-19 2017-05-24 The Wwk Trust Combinations for the treatment of dementia, and the enhancement of cognitive function
WO2018076108A1 (en) * 2016-10-25 2018-05-03 Uti Limited Partnership Treatment for progressive multiple sclerosis
WO2018200381A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
EP3431491A1 (en) * 2017-07-18 2019-01-23 Centre National De La Recherche Scientifique Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1497306A (en) * 1975-07-03 1978-01-05 Leo Ab Preparation of lofepramine and its hydrochloride
GB2082910A (en) * 1980-08-28 1982-03-17 Berk Pharmaceuticals Ltd Anti-depressant compositions
US4409243A (en) * 1981-11-09 1983-10-11 Julian Lieb Treatment of auto-immune and inflammatory diseases
GB2129299A (en) * 1982-11-09 1984-05-16 Alec James Coppen Pharmaceutical compositions
DE3519687A1 (de) * 1985-06-01 1986-12-04 Veit Arend Aminosaeuren enthaltendes arzneimittel
US4650789A (en) * 1985-10-15 1987-03-17 Commonwealth Medical Corporation Of America Method and composition for increasing production of serotonin
US4843071A (en) * 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
DE4204102C2 (de) * 1992-02-12 1998-09-24 Kragler Peter Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen

Also Published As

Publication number Publication date
DE69528773T2 (de) 2003-09-04
HU225493B1 (en) 2007-01-29
NO971539D0 (no) 1997-04-04
SK43897A3 (en) 1998-08-05
AU3612695A (en) 1996-05-02
PT784476E (pt) 2003-03-31
FI971290A0 (fi) 1997-03-26
NO971539L (no) 1997-04-04
US6096737A (en) 2000-08-01
HUT77380A (hu) 1998-04-28
WO1996011009A1 (en) 1996-04-18
US6569850B1 (en) 2003-05-27
AU710339B2 (en) 1999-09-16
EP0784476A1 (en) 1997-07-23
ATE227124T1 (de) 2002-11-15
NO314486B1 (no) 2003-03-31
NZ293642A (en) 1998-10-28
IS4454A (is) 1997-03-26
FI971290L (fi) 1997-06-02
FI116659B (fi) 2006-01-31
EP0784476B1 (en) 2002-11-06
CA2200761C (en) 2008-02-26
CZ99597A3 (en) 1997-11-12
SK281932B6 (sk) 2001-09-11
IS1956B (is) 2004-11-15
DE69528773D1 (de) 2002-12-12
DK0784476T3 (da) 2003-03-17
PL181802B1 (en) 2001-09-28
JPH10508583A (ja) 1998-08-25
PL319830A1 (en) 1997-09-01
CZ293873B6 (cs) 2004-08-18
CA2200761A1 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
CA2200761A1 (en) Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound
ES2144119T3 (es) Uso de inhibidores de la ciclooxigenasa no esteroideos para la fabricacion de un medicamento para el tratamiento de una presion intraocular elevada.
MX9203444A (es) Medicamentos.
ES2128552T3 (es) Combinacion de un inhibidor de la biosintesis del colesterol y un inhibidor de la absorcion del colesterol beta-lactama.
KR920019347A (ko) 당뇨병의 치료방법
BR9911408A (pt) Formas de dosagem contendo apomorfina paramelhora de disfunção erétil masculina
ES2149264T3 (es) Agente terapeutico para el tratamiento de melanomas.
ES2161288T3 (es) Comprimido revestido con polimero que comprende amoxicilina y clavulanato.
ES2157958T3 (es) Uso de venlafaxina o de un compuesto de ariloxipropanamina para la preparacion de un medicamento para el tratamiento de la incontinencia urinaria.
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
CO5160365A1 (es) Celulosa microfibrilar estabilizada
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
DK0921787T3 (da) Indgivelsesdosering af H+, K+ -ATPase-inhibitorer
HUP9901360A2 (hu) Cimicifuga racemosa-ból származó extraktum alkalmazása
ES2193233T3 (es) Uso de amiodipina, una sal de la misma o felodipina en combinacion con un inhibidor ace en la fabricacion de un medicamento para el tratamiento de insuficiencia cardiaca conjuntiva no isquemica.
KR900007424A (ko) 세포보호성 약제로서의 n-아세틸글루코사민의 사용방법 및 그 조성물
ES2196167T3 (es) Composicion farmaceutica que contiene propionato de 3-(2,2,2-trimetilhidrazinio) y gamma-butirobetaina para el tratamiento de enfermedades cardiovasculares.
IL72900A (en) Spiro-tricyclic aromatic succinimide derivatives and pharmaceutical compositions for inhibiting aldose reductase
NO20012351L (no) Farmasoytisk sammensetning for modifisert frigjoring av insulinsensibiliserende middel
MY121604A (en) Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt
ES2116429T3 (es) Composicion que contiene l-carnitina o acil-l-carnitina en combinacion con un inhibidor de ace para el tratamiento de trastornos cardiovasculares.
AR016350A1 (es) Uso de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa para prepararmedicamentos
ES2176702T3 (es) Antimicoticos con alta liberacion de sustancia activa.